We also found medication with SGLT2 inhibitors was connected with a higher risk of infections, osmotic diuresis-related AEs, volume-related AEs, renal-related AEs, and hypoglycaemia when randomized clinical trials evidence were pooled (Shi et al., 2019). The gene discussed is SLC5A2; the disease is Hypoglycemia.